Human Papillomavirus

Human Papillomavirus - most related articles:

- Gardasil HPV vaccine prevented genital lesions in men - 3.8
- Persistent HPV infection raises cervical cancer risk - 3.2
- IUDs may lower cervical cancer risk - 2.8
- Gardasil approval delayed for use in women ages 27 - 45 - 2.6
- Gardasil efficacious against HPV 16 infection - 2.4
- Tattooing improves DNA vaccine response - 2.3
- Alarming rates of STDs among teenage girls - 2.3
- Gardasil vaccine to prevent cervical cancer in India - 2.3
- Gardasil approved to prevent anal cancer - 2.2
- Gardasil is eligible for UN immunization programs - 2.1

Human Papillomavirus articles

HPV vaccine reduces subsequent cervical disease in women
HPV vaccination does not reduce progression to cervical disease in women, but vaccinated women had less frequent subsequent cervical disease. Women who are diagnosed with pre-cancerous cervical conditions after receiving the HPV vaccine can still benefit from a considerably reduced risk of reoccurring disease.

HPV DNA testing for all women aged 29 years and above
Implementation of HPV DNA testing in cervical screening leads to earlier detection of clinically relevant CIN grade 2 or worse, which when adequately treated, improves protection against CIN grade 3 or worse and cervical cancer. Early detection of high-grade cervical legions caused by HPV16 was a major component of this benefit.

Cervical cancer virus HPV linked to oral cancer rise
A new study of oropharyngeal cancer suggests that dramatic increases in U.S. incidence of the cancer and survival since 1984 can be attributed to infection with the human papillomavirus (HPV).

IUDs may lower cervical cancer risk
IUDs or intrauterine contraceptive devices could substantially reduce the risk of women developing cervical cancer, revealed by researchers in a recent study in Lancet Oncology.

Gardasil approved to prevent anal cancer
The U.S. Food and Drug Administration today approved the vaccine Gardasil for the prevention of anal cancer and associated precancerous lesions due to human papillomavirus (HPV) types 6, 11, 16, and 18 in people ages 9 through 26 years.

Frequent screening for women over 41 is low after HPV Vaccination
The overall potential benefits of human papillomavirus (HPV) vaccinations or frequent HPV screenings for women over the age of 41 are low, concludes a new study published online February 15 in the Journal of the National Cancer Institute.

Cervical cancer screening should be less frequent
Women should have their first cervical cancer screening at age 21 and can be rescreened less frequently than previously recommended, reported by US researchers at ACOG.

Breast cancer drugs may prevent cervical cancer also
Researchers eliminated cervical cancer in mice with two FDA-approved drugs currently used to treat breast cancer and osteoporosis. The study is published in the Proceedings of the National Academy of Sciences.

GSK's cervical cancer vaccine Cervarix got WHO prequalification
The World Health Organization (WHO) has awarded prequalification to Cervarix, GlaxoSmithKline's cervical cancer vaccine. GlaxoSmithKline pharmaceutical company applied for WHO prequalification of Cervarix 2 years ago.

Early cervical cancer screening may harm women
UK's Advisory Committee on Cervical Screening (ACCS) has agreed unanimously for no change in the screening age as evidence showed that earlier screening could do more harm than good causing too many false positives and increase the risk of premature births in some women.

New gene silencing way to turn off cervical cancer genes
Researchers at The University of Queensland have developed a way to deliver drugs which can specifically shut down cancer-causing genes in tumour cells while sparing normal healthy tissues.

Benefit to women not enough to sway men to get HPV vaccine
Informing men that a new vaccine to prevent human papillomavirus (HPV) would also help protect their female partners against developing cervical cancer from the sexually transmitted infection did not increase their interest in getting the vaccine, according to a new Florida State University study.

Gardasil is eligible for UN immunization programs
GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], Merck's cervical cancer vaccine, has been awarded World Health Organization (WHO) pre-qualification. GARDASIL is the first cervical cancer vaccine to receive WHO pre-qualification.

Gardasil efficacious against HPV 16 infection
In a study of an extended follow up of 290 women naïve to HPV type 16, the HPV 16 component of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] was efficacious against HPV 16 infection for an average of 8.5 years after administration.

Cervical cancer screening to 50000 women in India
QIAGEN and the Chittaranjan National Cancer Institute (CNCI) announced a collaboration to establish the first large-scale cervical cancer screening program for women in Kolkata, India.

Cervical cancer screening might safely be delayed after HPV vaccine
DNA from human papilloma virus type 16 (HPV16) and HPV type 18 (HPV18) were found in the majority of invasive cervical cancers in New Mexico in the 1980s and 1990s, according to a population-based study published in the March 24 online issue of the Journal of the National Cancer Institute.

TV ad to educate women about cervical cancer and HPV test
Through a new advertising campaign being launched in US, local women will soon learn more about cervical cancer screening and prevention.

Gardasil approval delayed for use in women ages 27 - 45
Merck & Co., Inc. announced that the U.S. Food and Drug Administration has issued a second complete response letter regarding the supplemental biologics license application (sBLA) for the use of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] in women ages 27 though 45.

HPV vaccine's hypersensitivity reactions are rare
Hypersensitivity reactions to the quadrivalent HPV vaccine (4vHPV, Gardasil) are uncommon and most schoolgirls can tolerate subsequent doses, finds the first evaluation of the quadrivalent HPV vaccine published on bmj.com.

Gardasil HPV vaccine prevented genital lesions in men
GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant], the cervical cancer vaccine from Merck & Co., Inc., prevented 90 percent of external genital lesions caused by human papillomavirus (HPV) types 6, 11, 16 and 18 in a pivotal Phase III study in men aged 16 to 26.

QIAGEN's careHPV test provides more accurate screening
A new HPV test developed by QIAGEN specifically for use in regions of the world with scarce resources is "substantially" more accurate in identifying women with cervical disease than the current methods (Pap testing and visual inspection) in these countries.

Persistent HPV infection raises cervical cancer risk
Persistent infection with human papillomavirus (HPV) could be a useful clinical marker for increased risk of cervical cancer, the second most common cancer in women worldwide, revealed by researchers from the University of North Carolina at Chapel Hill.

Mothers less likely to vaccinate daughters against HPV
U.S. mothers report they are less likely to vaccinate daughters under age 13 against human papillomavirus virus (HPV), even though the vaccine is recommended for girls at age 11 and 12, it's incumbent upon the healthcare community to work to improve mom's acceptance of the vaccination for younger daughters, say researchers at Cincinnati Children's Hospital Medical Center who conducted the study.

Stress may increase cervical cancer risk
A woman's daily stress can reduce her ability to fight off a common sexually transmitted disease and increase her risk of developing the cancer it can cause, according to a new study. No such association is seen, however, between past major life events, such as divorce or job loss, and the body's response to the infection.

24 Human Papillomavirus articles listed above.

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
2.11